APRE today
$0.45+$0.00 (+0.27%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $9.90
Key levels
Resistance$0.53
Resistance$0.46
Latest news & SEC filings
EarningsAprea Therapeutics Posts Q3 2026 Results, Business Update
SEC FilingAprea Therapeutics, Inc. filed a report on a major company event (Form 8-K)
EarningsAprea Therapeutics posts wider third-quarter loss than expected
All APRE news →About Aprea Therapeutics
Aprea Therapeutics is a clinical-stage oncology company developing targeted treatments for cancers with specific genetic biomarkers. Its lead candidates are an oral WEE1 inhibitor and an oral ATR inhibitor, both in early clinical testing for advanced solid tumors, plus a preclinical DYRK1 inhibitor. The company operates in the United States and holds worldwide rights to its candidates.
Based on the company's 10-K filed Mar 16, 2026.
Nasdaq · Healthcare
Aprea Therapeutics, Inc. (APRE)
What Is the Price Target for APRE?
SEPT Low Target
$1.20
SEPT Mid Target
$2.50
SEPT High Target
$5.00
Analyst Consensus
$2.50
Is APRE a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for APRE.
Start Free Trial →Is APRE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$2.33
0
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with APRE?
Insider Signal
NEUTRAL
2 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →APRE Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
17.87%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for APRE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for APRE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:02:51 | $0.44 | 4,493 | $$2K | SELL |
| 16:24:52 | $0.44 | 1,923 | $$845 | SELL |
| 16:10:27 | $0.44 | 4,000 | $$2K | SELL |
| 14:55:50 | $0.44 | 3,638 | $$2K | BUY |
| 14:50:50 | $0.44 | 4,747 | $$2K | SELL |
5 dark pool trades shown · $$8K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Aprea Therapeutics, Inc. (APRE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →APRE — frequently asked questions
What is APRE stock price today?
Aprea Therapeutics, Inc. (APRE) is at $0.45, up 0.27% (+$0.00) at the Nov 11, 2026 close.
Why is APRE stock moving today?
Latest APRE news — Nov 5, 2026: Aprea Therapeutics Posts Q3 2026 Results, Business Update · Nov 4, 2026: Aprea Therapeutics, Inc. filed a report on a major company event (Form 8-K)
What is the APRE price target?
The average analyst price target for APRE is $2.50, ranging from $1 to $5, based on 4 analysts. Latest: Ladenburg Thalmann initiates on Oct 14, 2026.
What do analysts rate APRE?
Analyst ratings for APRE: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did APRE beat earnings?
APRE last reported on Aug 12, 2026: EPS -$0.07 vs -$0.18 expected — a beat of 60.6%.
Does APRE pay a dividend?
APRE does not currently pay a dividend.
What are APRE support and resistance levels?
Resistance: $0.46, $0.53, $0.60.
What are insiders doing with APRE?
Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.
What is the latest news on APRE?
Nov 5, 2026: Aprea Therapeutics Posts Q3 2026 Results, Business Update · Nov 4, 2026: Aprea Therapeutics, Inc. filed a report on a major company event (Form 8-K) · Nov 4, 2026: Aprea Therapeutics posts wider third-quarter loss than expected